RhumbLine Advisers’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $85.5M | Sell |
1,067,753
-9,749
| -0.9% | -$804K | 0.07% | 228 |
|
|
2025
Q4 | $91.9M | Sell |
1,077,502
-34,285
| -3% | -$2.81M | 0.07% | 209 |
|
|
2025
Q3 | $86.5M | Buy |
1,111,787
+15,792
| +1% | +$1.23M | 0.07% | 233 |
|
|
2025
Q2 | $85.7M | Sell |
1,095,995
-34,159
| -3% | -$2.55M | 0.07% | 222 |
|
|
2025
Q1 | $81.9M | Buy |
1,130,154
+44,249
| +4% | +$3.17M | 0.08% | 227 |
|
|
2024
Q4 | $80.4M | Sell |
1,085,905
-37,002
| -3% | -$2.59M | 0.07% | 220 |
|
|
2024
Q3 | $74.1M | Sell |
1,122,907
-73,240
| -6% | -$5.32M | 0.07% | 247 |
|
|
2024
Q2 | $110M | Sell |
1,196,147
-42,373
| -3% | -$3.75M | 0.1% | 161 |
|
|
2024
Q1 | $118M | Buy |
1,238,520
+7,323
| +0.6% | +$615K | 0.11% | 160 |
|
|
2023
Q4 | $93.9M | Sell |
1,231,197
-7,402
| -0.6% | -$515K | 0.1% | 177 |
|
|
2023
Q3 | $85.8M | Sell |
1,238,599
-17,588
| -1% | -$1.41M | 0.1% | 173 |
|
|
2023
Q2 | $118M | Buy |
1,256,187
+9,826
| +0.8% | +$854K | 0.13% | 131 |
|
|
2023
Q1 | $103M | Buy |
1,246,361
+65,937
| +6% | +$5.18M | 0.13% | 144 |
|
|
2022
Q4 | $88.1M | Buy |
1,180,424
+32,133
| +3% | +$2.48M | 0.12% | 165 |
|
|
2022
Q3 | $94.9M | Buy |
1,148,291
+19,525
| +2% | +$1.88M | 0.14% | 132 |
|
|
2022
Q2 | $107M | Buy |
1,128,766
+21,812
| +2% | +$2.26M | 0.16% | 119 |
|
|
2022
Q1 | $130M | Buy |
1,106,954
+30,106
| +3% | +$3.38M | 0.17% | 105 |
|
|
2021
Q4 | $140M | Sell |
1,076,848
-1,950
| -0.2% | -$227K | 0.17% | 102 |
|
|
2021
Q3 | $122M | Sell |
1,078,798
-11,416
| -1% | -$1.3M | 0.17% | 109 |
|
|
2021
Q2 | $113M | Sell |
1,090,214
-58,922
| -5% | -$5.55M | 0.15% | 120 |
|
|
2021
Q1 | $96.1M | Sell |
1,149,136
-51,321
| -4% | -$4.34M | 0.13% | 136 |
|
|
2020
Q4 | $110M | Sell |
1,200,457
-8,628
| -0.7% | -$716K | 0.15% | 128 |
|
|
2020
Q3 | $96.5M | Buy |
1,209,085
+5,841
| +0.5% | +$456K | 0.15% | 126 |
|
|
2020
Q2 | $83.2M | Sell |
1,203,244
-45,551
| -4% | -$3.24M | 0.14% | 136 |
|
|
2020
Q1 | $78.5M | Buy |
1,248,795
+31,335
| +3% | +$2.26M | 0.16% | 123 |
|
|
2019
Q4 | $94.7M | Buy |
1,217,460
+67,851
| +6% | +$5.3M | 0.16% | 124 |
|
|
2019
Q3 | $84.3M | Buy |
1,149,609
+9,825
| +0.9% | +$690K | 0.15% | 133 |
|
|
2019
Q2 | $70.2M | Buy |
1,139,784
+17,037
| +2% | +$1.03M | 0.13% | 151 |
|
|
2019
Q1 | $71.6M | Sell |
1,122,747
-25,218
| -2% | -$1.44M | 0.14% | 140 |
|
|
2018
Q4 | $58.6M | Sell |
1,147,965
-47,226
| -4% | -$2.39M | 0.13% | 152 |
|
|
2018
Q3 | $69.4M | Sell |
1,195,191
-31,191
| -3% | -$1.53M | 0.13% | 148 |
|
|
2018
Q2 | $59.5M | Buy |
1,226,382
+44,190
| +4% | +$2.06M | 0.12% | 171 |
|
|
2018
Q1 | $55M | Sell |
1,182,192
-31,008
| -3% | -$1.35M | 0.11% | 184 |
|
|
2017
Q4 | $45.6M | Buy |
1,213,200
+32,943
| +3% | +$1.21M | 0.09% | 218 |
|
|
2017
Q3 | $43M | Sell |
1,180,257
-16,032
| -1% | -$611K | 0.09% | 224 |
|
|
2017
Q2 | $47.1M | Sell |
1,196,289
-8,352
| -0.7% | -$305K | 0.11% | 198 |
|
|
2017
Q1 | $37.8M | Buy |
1,204,641
+14,418
| +1% | +$451K | 0.09% | 239 |
|
|
2016
Q4 | $37.2M | Buy |
1,190,223
+60,111
| +5% | +$1.95M | 0.09% | 221 |
|
|
2016
Q3 | $45.4M | Buy |
1,130,112
+22,587
| +2% | +$851K | 0.13% | 168 |
|
|
2016
Q2 | $36.8M | Buy |
1,107,525
+38,622
| +4% | +$1.32M | 0.11% | 194 |
|
|
2016
Q1 | $31.4M | Buy |
1,068,903
+48,468
| +5% | +$1.34M | 0.1% | 208 |
|
|
2015
Q4 | $26.9M | Buy |
1,020,435
+10,743
| +1% | +$279K | 0.09% | 227 |
|
|
2015
Q3 | $23.9M | Buy |
1,009,692
+3,300
| +0.3% | +$79.7K | 0.08% | 249 |
|
|
2015
Q2 | $23.9M | Buy |
1,006,392
+82,266
| +9% | +$1.86M | 0.08% | 257 |
|
|
2015
Q1 | $21.9M | Buy |
924,126
+18
| +0% | +$404 | 0.06% | 271 |
|
|
2014
Q4 | $19.6M | Sell |
924,108
-28,098
| -3% | -$564K | 0.06% | 300 |
|
|
2014
Q3 | $16.2M | Sell |
952,206
-1,620
| -0.2% | -$25.6K | 0.05% | 336 |
|
|
2014
Q2 | $13.6M | Sell |
953,826
-71,310
| -7% | -$967K | 0.04% | 397 |
|
|
2014
Q1 | $12.7M | Sell |
1,025,136
-37,884
| -4% | -$437K | 0.04% | 416 |
|
|
2013
Q4 | $11.7M | Sell |
1,063,020
-97,278
| -8% | -$1.1M | 0.03% | 442 |
|
|
2013
Q3 | $13.5M | Sell |
1,160,298
-4,098
| -0.4% | -$47.9K | 0.04% | 398 |
|
|
2013
Q2 | $13M | Buy |
+1,164,396
| New | +$13.8M | 0.04% | 385 |
|
Other funds holding EW
VCM
VPM
RhumbLine Advisers's EW Position: Q1 2026 in Review
RhumbLine Advisers reduced its Edwards Lifesciences (EW) stake by 0.9% in Q1 2026, selling an estimated $804K and leaving 1,067,753 shares worth $85.5M. The position accounts for 0.07% of the portfolio, ranked #228.
RhumbLine Advisers first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $140M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- RhumbLine Advisers held 1,067,753 shares of Edwards Lifesciences worth $85.5M as of Q1 2026.
- RhumbLine Advisers sold 9,749 Edwards Lifesciences shares in Q1 2026, an estimated $804K.
- Edwards Lifesciences made up 0.07% of RhumbLine Advisers's portfolio in Q1 2026, its #228 holding.
- RhumbLine Advisers first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- RhumbLine Advisers's Edwards Lifesciences position peaked at $140M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.